Skip to content
Arrevus logo

Arrevus Alternatives & Competitors

12 companies similar to Arrevus — Conquering antibiotic resistance by targeting critical diseases with innovative...

Companies similar to Arrevus

Arpida logo — alternative to Arrevus
Bugworks Research Inc. logo — alternative to Arrevus

Bugworks Research Inc.

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-...

Clarametyx Biosciences logo — alternative to Arrevus

Clarametyx Biosciences

Targeting biofilms to treat chronic respiratory disease

Phico Therapeutics Ltd. logo — alternative to Arrevus

Phico Therapeutics Ltd.

Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance w...

Rival Readout

Competing with Arrevus? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
PolyPid Ltd.  logo — alternative to Arrevus

PolyPid Ltd.

Controlled, extended-release, local delivery of medication at effective release rates over...

ALSP, Inc. logo — alternative to Arrevus

ALSP, Inc.

Pioneering small molecule therapies for neurodegenerative diseases, focusing on innovative...

Spero Therapeutics logo — alternative to Arrevus

Spero Therapeutics

Clinical-stage biotech company focused on rare diseases and diseases with high unmet need

Biohaven logo — alternative to Arrevus

Biohaven

A modern pharmaceutical company guided by science and inspired to change the lives of peop...

Sealife PHARMA® GMBH logo — alternative to Arrevus

Sealife PHARMA® GMBH

Pioneering breakthroughs in marine biochemistry to combat drug-resistant infections and ad...

Allecra Therapeutics logo — alternative to Arrevus

Allecra Therapeutics

Our Mission: Answering the call to action to fight antibiotic resistance

KBP Biosciences logo — alternative to Arrevus

KBP Biosciences

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

Adaptive Phage Therapeutics logo — alternative to Arrevus

Adaptive Phage Therapeutics

To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cu...

About Arrevus

Arrevus is a biotechnology and pharmaceutical startup, founded in 2015, with a mission to address antibiotic resistance in critical diseases. The company's focus lies in developing Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs) for diseases where antibiotic resistance has significant cl...

Business keywords

Antibiotic Resistance, DPCs, Drug Development, Clinical Implications, Bacterial Resistance, MRSA, Antimicrobial Peptides, Life-threatening Diseases, Patient Outcomes, Innovative Therapies, Pharmaceutical Research, Biomedical Innovation

Frequently Asked Questions

Companies similar to Arrevus include Arpida, Bugworks Research Inc., Clarametyx Biosciences, Phico Therapeutics Ltd., PolyPid Ltd. . They work in Biotechnology and Pharmaceutical and share Arrevus's focus on drug development, antibiotic resistance and mrsa.
Bounce Watch lists 12 companies that share Arrevus's industries and are closest to it in business tags, services, target customers, business model and size.
Arrevus is a biotechnology and pharmaceutical startup, founded in 2015, with a mission to address antibiotic resistance in critical diseases. The company's focus lies in developing Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs) for diseases where antibiotic resistance has significant cl...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Arrevus: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at Arrevus on 12 Sep 2024. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout